| Literature DB >> 23786878 |
Fernanda S Oliveira1, Cláudia M Valete-Rosalino, Sandro J B Pacheco, Filipe A Carvalho Costa, Armando O Schubach, Raquel S Pacheco.
Abstract
BACKGROUND: The genetic variability of Leishmania (Viannia) braziliensis was assessed at intra and interpatient levels of individuals with different clinical manifestations of American tegumentary leishmaniasis (ATL).Entities:
Mesh:
Substances:
Year: 2013 PMID: 23786878 PMCID: PMC3729673 DOI: 10.1186/1756-3305-6-189
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Clinical and epidemiological characteristics of the 35 patients analysed in this study
| 1 | 52 | M | MCL | Arm/1MCL-C | Oral / 1MCL-O |
| 2 | 48 | M | MCL | Nostril/2MCL-C | Oral/2MCL-O |
| 3 | 25 | M | MCL | Arm/3MCL-C | Nasal/3MCL-N |
| 4 | 54 | M | MCL | ND | Oral/4MCL-O |
| 5 | 47 | M | MCL | Arm/5MCL-C | Nasal/5MCL-N |
| Oral/5MCL-O | |||||
| 6 | 16 | M | MCL | ND | Nasal/6MCL-N |
| 7 | 50 | M | MCL | Face/7MCL-C | Nasal/7MCL-N |
| 8 | 29 | M | MCL | Trunk/8LMC-C | Nasal/8MCL-N |
| 9 | 55 | M | MCL | ND | Oral/9MCL-O |
| 10 | 42 | M | MCL | ND | Nasal/10MCL-N |
| 11 | 52 | F | MCL | Arm/11MCL-C | Nasal/11MCL-N |
| 12 | 25 | M | MCL | Trunk/12MCL-C | Oral/12MCL-O |
| 13 | 52 | F | MCL | ND | Oral/13MCL-O |
| 14 | 54 | M | MCL | Upper lip/14MCL-C | Nasal/14MCL-N |
| 15 | 69 | M | MCL | ND | Nasal/15MCL-N |
| 16 | 65 | M | MCL | ND | Oral/16MCL-O |
| 17 | 63 | F | ML | A | Nasal/17ML-N |
| 18 | 53 | M | ML | A | Nasal/18ML-N |
| 19 | 66 | F | ML | A | Nasal/19ML-N |
| 20 | 71 | M | ML | A | Nasal/20ML-N |
| 21 | 12 | M | ML | A | Nasal/21ML-N |
| 22* | 49 | F | ML | A | Nasal/22ML-N |
| 23* | 69 | M | ML | A | Nasal/23ML-N |
| 24* | 60 | M | ML | A | Nasal/24ML-N |
| 25* | 77 | M | ML | A | Nasal/25ML-N |
| 26* | 72 | M | ML | A | Nasal/26ML-N |
| 27* | 71 | F | ML | A | Nasal/27ML-N |
| 28* | 39 | M | ML | A | Nasal/28ML-N |
| 29* | 63 | M | ML | A | Nasal/29ML-N |
| 30* | 44 | F | ML | A | Nasal/30ML-N |
| 31* | 31 | F | ML | A | Nasal/31ML-N1 |
| Nasal/31ML-N2 | |||||
| 32* | 29 | F | ML | A | Nasal/32ML-N1 |
| Nasal/32ML-N2 | |||||
| 33* | 72 | F | ML | A | Oral/33LM-O |
| 34 | 49 | M | DL | Arm/ 34DL-C1 | Nasal/34DL-N |
| Trunk/34DL-C2 | |||||
| Leg/34DL-C3 | |||||
| 35 | 41 | M | DL | Nose/35DL-C | Nasal/35DL-N |
| Oral/35DL-O | |||||
*, Patients reporting the absence of an initial cutaneous lesion or scar suggestive of leishmaniasis; M male, F female, MCL, mucocutaneous leishmaniasis, ML mucosal leishmaniasis, DL disseminated leishmaniasis, ND not done, A absence of cutaneous lesion at the time of clinical evaluation.
Figure 1kDNA signatures of obtained by LSSP-PCR and phenetic analysis. A: 1.8% High Resolution agarose gel electrophoresis showing representative genetic profiles derived from amplification of the 750 bp fragment from mucosal lesions of different patients. Lanes: M – Molecular marker (100 bp ladder); lanes 1–5: 22ML-N, 26ML-N, 29ML-N, 4MCL-O and 16MCL-O; lanes 6–12: 11MCL-N, 11MCL-C, 3MCL-N, 3MCL-C, 5MCL-N, 5MCL-O and 5MCL-C. B: UPGMA dendrogram showing the “Simple Matching” coefficients of similarity based on the genetic profiles obtained by LSSP-PCR. Lb, L. (V.) braziliensis reference strain (MHOM/BR/1975/M2903). MCL: mucocutaneous leishmaniasis; ML: mucosal leishmaniasis; DL: disseminated leishmaniasis; N: nasal; O: oral; C: cutaneous; C1-C3: different samples of cutaneous lesions collected at different moments; N1 and N2: different samples of mucosal nasal lesions collected at different moments.
Table showing the values of the intra- and interpatient coefficients of similarity of selected representative samples
| 5MCL-C | 1.00 | | | | | | | | | | | | | | | |
| 5MCL-N | 0.77 | 1.00 | | | | | | | | | | | | | | |
| 5MCL-O | 0.77 | 0.94 | 1.00 | | | | | | | | | | | | | |
| 12MCL-C | 0.66 | 0.72 | 0.72 | 1.00 | | | | | | | | | | | | |
| 12MCL-0 | 0.72 | 0.72 | 0.72 | 0.94 | 1.00 | | | | | | | | | | | |
| 34DL-N | 0.69 | 0.58 | 0.58 | 0.69 | 0.69 | 1.00 | | | | | | | | | | |
| 34DL-C1 | 0.55 | 0.61 | 0.66 | 0.66 | 0.66 | 0.75 | 1.00 | | | | | | | | | |
| 34DL-C2 | 0.69 | 0.58 | 0.63 | 0.75 | 0.75 | 0.77 | 0.75 | 1.00 | | | | | | | | |
| 34DL-C3 | 0.72 | 0.72 | 0.72 | 0.66 | 0.66 | 0.69 | 0.77 | 0.75 | 1.00 | | | | | | | |
| 31 M1-N1 | 0.66 | 0.72 | 0.72 | 0.77 | 0.77 | 0.63 | 0.66 | 0.63 | 0.66 | 1.00 | | | | | | |
| 31ML-N2 | 0.50 | 0.55 | 0.50 | 0.55 | 0.61 | 0.58 | 0.55 | 0.52 | 0.50 | 0.55 | 1.00 | | | | | |
| 9MCL-O | 0.72 | 0.66 | 0.66 | 0.77 | 0.83 | 0.69 | 0.55 | 0.75 | 0.61 | 0.72 | 0.66 | 1.00 | | | | |
| 15MCL-N | 0.75 | 0.63 | 0.63 | 0.80 | 0.80 | 0.72 | 0.69 | 0.72 | 0.75 | 0.86 | 0.58 | 0.75 | 1.00 | | | |
| 23ML-N | 0.63 | 0.63 | 0.63 | 0.75 | 0.69 | 0.66 | 0.58 | 0.66 | 0.58 | 0.80 | 0.52 | 0.69 | 0.83 | 1.00 | | |
| 20ML-N | 0.72 | 0.77 | 0.77 | 0.77 | 0.83 | 0.63 | 0.61 | 0.63 | 0.61 | 0.83 | 0.55 | 0.83 | 0.69 | 0.69 | 1.00 | |
| 33ML-O | 0.66 | 0.61 | 061 | 0.77 | 0.77 | 0.69 | 0.67 | 0.69 | 0.66 | 0.72 | 0.66 | 0.72 | 0.80 | 0.75 | 0.72 | 1.00 |
MCL mucocustaneous leishmaniasis, DL disseminated leishmaniasis, ML mucosal leishmaniasis, N nasal lesion, O oral lesion, C custaneous lesion, N1 and N2 nasal lesion fragments collected at 2 different times, C1-C3 cutaneous lesion fragments collected at different times.
Figure 2Conceptual model proposed by Pacheco RS and Oliveira FS aiming to explain the dynamics of the circulating populations of at both intra and interpatient levels in a specific endemic area. At interpatient level, heterogeneous subpopulations (A-E) circulate among man, vectors, domestic and sylvatic animals and such individuals would be exposed to distinct selective pressures, to the polyclonality of the initial inoculum and also to multiple independent infections. At intrapatient level, the individual may act as a biological filter and the situation takes into account the participation of both parasite virulence factors and the immunological system of the host.